Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: Systematic review

Lancet Oncology

Volumn 5, Issue 9, 2004, Pages 531-540

  Vansteenkiste, Johanjohan ^a   Fischer, Barbara M ^b   Dooms, Christophe ^a   Mortensen, Jann ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; PLATINUM DERIVATIVE;

ADVANCED CANCER; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAL DOCUMENTATION; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PUBLICATION; RECURRENT CANCER; REVIEW; SENSITIVITY ANALYSIS; STANDARDIZATION; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4444364812     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01564-5     Document Type: Review

References (49)

1. Vansteenkiste J.F. Stroobants S.G. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology Eur Respir J 17 2001 802-820
2. Woodard H.Q. Bigler R.E. Freed B. Russ G. Expression of tissue isotope distribution J Nucl Med 16 1975 958-959
3. Fischer B.M. Mortensen J. Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review Lancet Oncol 2 2001 659-666
4. Gould M.K. Maclean C.C. Kuschner W.G. et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis JAMA 285 2001 914-924
5. Dwamena B.A. Sonnad S.S. Angobaldo J.O. Wahl R.L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT Radiology 213 1999 530-536
6. Toloza E.M. Harpole L. McCrory D.C. Noninvasive staging of non-small cell lung cancer: a review of the current evidence Chest 123 1 suppl 2003 137S-146S
7. Pieterman R.M. Van Putten JW Meuzelaar JJ et al. Preoperative staging of non-small cell lung cancer with positron emission tomography N Engl J Med 343 2000 254-261
8. Duhaylongsod FG Lowe VJ Patz EF et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography Ann Thorac Surg 60 1995 1348-1352
9. Ahuja V Coleman RE Herndon J Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma Cancer 83 1998 918-924
10. Vansteenkiste JF Stroobants SG De Leyn PR et al. Prognostic importance of the Standardized Uptake Value on FDG-PET-scan in non-small cell lung cancer: an analysis of 125 cases J Clin Oncol 17 1999 3201-3206
11. Dhital K Saunders CA Seed PT et al. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer Eur J Cardiothorac Surg 18 2000 425-428
12. Higashi K Ueda Y Arisaka Y et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer J Nucl Med 43 2002 39-45
13. Jeong HJ Min JJ Park JM et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer Nucl Med Commun 23 2002 865-870
14. Dunagan DP Chin R McCain TW et al. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer Chest 119 2001 333-339
15. MacManus MP Hicks RJ Ball DL et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment Cancer 92 2001 886-895
16. MacManus MP Wong K Hicks RJ et al. Early mortality after radical radiotherapy for non-small cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center Int J Radiat Oncol Biol Phys 52 2002 351-361
17. Hoekstra CJ Stroobants SG Hoekstra OS et al. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment Lung Cancer 39 2003 151-157
18. Feinstein AR Sosin DM Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer N Engl J Med 312 1985 1604-1608
19. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004; 350: 351-60.
20. Miller AB Hoogstraten B Staquet M Winkler A. Reporting results of cancer treatment Cancer 47 1981 207-214
21. Therasse P Arbuck SG Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205-216
22. Higashi K Clavo AC Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake J Nucl Med 34 1993 414-419
23. Ichiya Y Kuwabara Y Sasaki M et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma Ann Nucl Med 10 1996 193-200
24. Choi NC Fischman AJ Niemierko A et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small cell lung cancer Int J Radiat Oncol Biol Phys 54 2002 1024-1035
25. MacManus MP Hicks RJ Matthews JP et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer J Clin Oncol 21 2003 1285-1292
26. Weber WA Petersen V Schmidt B et al. Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 21 2003 2651-2657
27. Hoekstra CJ Hoekstra OS Stroobants SG et al.. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET J Nucl Med 43 2002 1304-1309
28. Young H Baum R Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations Eur J Cancer 35 1999 1773-1782
29. Bueno R Richards WG Swanson SJ et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival Ann Thorac Surg 70 2001 1826-1831
30. Voltolini L Luzzi L Ghiribelli C et al. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy Eur J Cardiothorac Surg 20 2001 1106-1112
31. Margaritora S Cesario A Galetta D et al. Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging? Eur J Cardiothorac Surg 19 2001 894-898
32. Vansteenkiste JF Stroobants SG De Leyn PR et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients J Clin Oncol 16 1998 2142-2149
33. Vansteenkiste JF Stroobants SG De Leyn PR et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 non-small cell lung cancer: a prospective pilot study Ann Oncol 9 1998 1193-1198
34. Akhurst T Downey RJ Ginsberg MS et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer Ann Thorac Surg 73 2002 259-266
35. Ryu JS Choi NC Fischman AJ et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology Lung Cancer 35 2002 179-187
36. Cerfolio RJ Ojha B Mukherjee S et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma J Thorac Cardiovasc Surg 125 2003 938-944
37. Vansteenkiste J. Stroobants S. Hoekstra C. et al. 18fluoro-2-deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy (IC) in stage IIIA-N2 NSCLC: a multi-center prospective study. Proc Am Soc Clin Oncol 2001 20 A313 (abstr).
38. Vesselle H Pugsley JM Vallieres E Wood DE. The impact of fluorodeoxyglucose F18 positron emission tomography on the surgical staging of non-small cell lung cancer J Thorac Cardiovasc Surg 124 2002 511-519
39. Patz EF Connolly J Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer AJR Am J Roentgenol 174 2000 769-774
40. Hicks RJ Kalff V Mac Manus MP et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification J Nucl Med 42 2001 1605-1613
41. Pandit N Gonen M Krug L Larson SM. Prognostic value of [(18)F]FDG-PET imaging in small cell lung cancer Eur J Nucl Med Mol Imaging 30 2003 78-84
42. Kubota K Yamada S Ishiwata K et al. Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: a preliminary study Eur J Nucl Med 20 1993 495-501
43. Patz EF Lowe VJ Hoffman JM et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose Radiology 191 1994 379-382
44. Duhaylongsod FG Lowe VJ Patz EF et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET) J Thorac Cardiovasc Surg 110 1995 130-139
45. Frank A Lefkowitz D Jaeger S et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings Int J Radiat Oncol Biol Phys 32 1995 1495-1512
46. Inoue T Kim EE Komaki R et al. Detecting recurrent or residual lung cancer with FDG-PET J Nucl Med 36 1995 788-793
47. Bury T Corhay JL Duysinx B et al. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer Eur Respir J 14 1999 1376-1380
48. Ukena D. Hellwig D. Palm I. et al. Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in diagnosis of recurrent bronchial carcinoma. Pneumologie 2000 54 49-53 (in German).
49. Lee J Aronchick JM Alavi A. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review Chest 120 2001 1791-1797